The role of a viral gene product in evasion of the host immune response was investigated. The antibodydependent complement-enhanced neutralization of vaccinia virus infectivity was prevented by the culture medium from vaccinia virus-infected cells. The vaccinia virus complementcontrol protein (VCP) was identified as the secreted product of vaccinia virus gene C21L and has homology to a group of eukaryotic genes encoding regulators of complement activation. Thus, the culture medium from cells infected with a C21L deletion mutant was VCP deficient and had little or no effect on antibody-dependent complement-enhanced neutralization. In addition, the anticomplement effect was associated with the C21L-encoded protein partially purified from the medium of cells infected with wild-type virus. Antibody-dependent, complement-enhanced neutralization of vaccinia virus occurred with a complement source that was deficient in the classical pathway complement component C4 and required the alternative pathway complement factor B. Furthermore, the presence of VCP abrogated the complement-enhanced neutralization in C4-deficient serum. Together with previous hemolysis data, the present result suggests that VCP can inhibit both the classical and alternative pathways of complement activation. Skin lesions caused by the C21L deletion mutant were smaller than those caused by wild-type virus, demonstrating an important role for VCP in virulence. The C21L deletion mutant also was attenuated in C4-deficient guinea pigs, consistent with in vitro studies. Vaccinia virus appears to have acquired the ability to regulate the complement cascade for the purpose of evading the host immune response.
ABSTRACT
The role of a viral gene product in evasion of the host immune response was investigated. The antibodydependent complement-enhanced neutralization of vaccinia virus infectivity was prevented by the culture medium from vaccinia virus-infected cells. The vaccinia virus complementcontrol protein (VCP) was identified as the secreted product of vaccinia virus gene C21L and has homology to a group of eukaryotic genes encoding regulators of complement activation. Thus, the culture medium from cells infected with a C21L deletion mutant was VCP deficient and had little or no effect on antibody-dependent complement-enhanced neutralization. In addition, the anticomplement effect was associated with the C21L-encoded protein partially purified from the medium of cells infected with wild-type virus. Antibody-dependent, complement-enhanced neutralization of vaccinia virus occurred with a complement source that was deficient in the classical pathway complement component C4 and required the alternative pathway complement factor B. Furthermore, the presence of VCP abrogated the complement-enhanced neutralization in C4-deficient serum. Together with previous hemolysis data, the present result suggests that VCP can inhibit both the classical and alternative pathways of complement activation. Skin lesions caused by the C21L deletion mutant were smaller than those caused by wild-type virus, demonstrating an important role for VCP in virulence. The C21L deletion mutant also was attenuated in C4-deficient guinea pigs, consistent with in vitro studies. Vaccinia virus appears to have acquired the ability to regulate the complement cascade for the purpose of evading the host immune response.
Higher eukaryotic organisms have developed an array of specific and nonspecific mechanisms to combat virus infections. Some viruses, however, have acquired genes encoding proteins that can modulate host responses. For example, down regulation of class I major histocompatibility antigens by an adenovirus protein may diminish cell-mediated immune responses (1), whereas membrane-associated glycoproteins of herpes simplex virus bind the Fc ends of immunoglobulins and may deflect humoral immune responses (2) . The importance of the complement system in host defense against viruses is emphasized by the discovery that members of at least two virus families, herpesviruses (3, 4) and poxviruses (5, 6) , encode proteins that interact with complement components.
The complement system has historically been divided into classical and alternative pathways that lead to the formation of a common membrane attack complex (7, 8) . Both pathways may be activated by the binding of complement components to immune complexes that form on viruses or virus-infected cells, although the alternative pathway can bypass this step (9) . In vitro studies suggest that virus particles coated with complement components may not attach to or enter cells efficiently or may be blocked at a subsequent stage of uncoating (10, 11) . Also, formation of the membrane attack complex can result in lysis of virions or infected cells. In vivo, additional mechanisms including the binding of complement-coated virus to the CR1 complement receptors of phagocytes and other cells and the release of anaphylactic and chemotactic complement peptides could also contribute to the immune response. Nevertheless, beneficial antiviral effects of complement have been more difficult to document in vivo than in vitro. Several studies have shown that mice depleted of complement may have prolonged viremia and high virus titers in affected organs (12) . Genetic deficiencies in complement components, however, are not generally associated with a greatly increased susceptibility to virus infections (13) .
The difficulty in demonstrating antiviral effects of complement in vivo, particularly by genetic methods, may be due at least in part to the host's multiplicity of specific and nonspecific immune defenses. Thus, the ability to clear viruses in the absence of complement does not mean that complement ordinarily plays no role in host defense but rather that there are efficient alternative mechanisms. Viruses (17) . The vaccinia virus complement-control protein (VCP) contains four short consensus repeats that are most similar in sequence (38% identity) to the first four repeats of the C4b binding protein (5) , a regulator of the classical complement pathway (18 
MATERIALS AND METHODS
Viruses. Vaccinia virus strain WR (American Type Culture Collection VR1354) was used for all neutralization studies.
Mutant vaccinia virus vSIGK3 was derived from the WR strain by replacing a 70-base-pair segment of the C21L gene with the selectable marker gene gpt (6) .
Source of VCP. Confluent monolayers of RK-13 cells (American Type Culture Collection CCL37) in flasks with a 150-cm2 surface area were washed with serum-free Opti-MEM (GIBCO) and then were infected with five plaqueforming units (pfu) per cell of vaccinia virus WR or vSIGK3 or were mock infected. The infected cells were maintained in 20 ml of serum-free Opti-MEM for 24 h at 370C in a 5% C02/95% air incubator. The medium was then collected from each flask and cell debris and extracellular virus were pelleted by ultracentrifugation at 13,500 rpm for 80 min in a Beckman SW27 rotor. The clarified medium was stored on ice or frozen at -200C. VCP was purified as described (6) .
Antibody to Vaccinia Virus. A rabbit (New Zealand White) was inoculated intradermally at multiple sites with both wild-type and vSIGK3 mutant vaccinia virus. After 6 weeks, the rabbit was given an intradermal inoculation of 108 pfu of wild-type virus at two sites. Two weeks later, the rabbit was bled by cardiac puncture. The immune serum was heated at 560C for 30 min to inactivate complement and was stored in aliquots at -70°C for use as antibody in the neutralization assays. An immunoglobulin G fraction was prepared with the AvidChrom antibody kit (BioProbe International, Richmond, CA) following the manufacturer's instructions and was used where indicated.
Complement. If received frozen, sera containing complement were thawed once and then stored as single-use aliquots at -70°C. Lyophilized sera were reconstituted in the recommended volume of cold deionized water and then aliquoted and frozen at -700C. Rabbit complement (fresh frozen; GIBCO), guinea pig complement (lyophilized; Sigma), guinea pig C4-deficient serum (fresh frozen; Sigma), and human complement (lyophilized; Sigma) were used where indicated. well. The plates were incubated for 36 h and stained with 0.2 ml of a 0.015% crystal violet solution. Plaques were counted at two dilutions under magnification (x6.5). Determination of Virus Pathogenicity. Dilutions (10-fold) of sucrose gradient-purified wild-type and vSIGK3 virus were made in sterile phosphate-buffered saline (Quality Biologicals) and 0.1-ml aliquots containing 101-106 pfu were injected intradermally down either side of the spine of the freshly shaved backs of New Zealand White rabbits. The diameters of the skin lesions were measured with calipers. A similar procedure was used to inoculate 2/NCR (National Cancer Institute, Frederick, MD) and C4-deficient guinea pigs (small animal section, National Institutes of Health) except that separate animals were used for wild-type and mutant viruses. (Fig. 1) . Rabbit complement enhanced the effect of antibody by -100-fold during a 180-min incubation but had only a small effect by itself (Fig.  1) . As expected, enhanced neutralization did not occur when the complement source was heat inactivated or when the incubation was performed in the presence of 10 mM EDTA (data not shown).
RESULTS

VCP Prevents
VCP is secreted into the medium of cells infected with vaccinia virus strain WR (5) . Addition of such medium prevented the complement-enhanced neutralization of vaccinia virus, whereas enhanced neutralization occurred in medium lacking VCP obtained from uninfected cells or from cells infected with the vaccinia virus deletion mutant vSIGK3 (Fig. 2) . These data implied that the product of the C21L gene interfered with complement-enhanced neutralization of vaccinia virus and that sufficient quantities of VCP were present in unconcentrated culture medium. A significant effect was obtained even when the culture medium was diluted 1:10 or when partially purified VCP (6) was used (data not shown).
105-. Effect of Deletion of the VCP Gene on Virus Pathogenicity in Rabbits. Previous studies (ref. 6 ; S.N.I., unpublished data) showed that deletion of the VCP gene had no effect on the growth of virus in tissue culture, consistent with a speculative role for this protein in defense against the immune system rather than for replication per se. Intradermal inoculation of vaccinia virus results in characteristic skin lesions, which persist over a 3-week period. We sought to determine whether expression of VCP was important for the development of these lesions. Accordingly, 1:10 dilutions of wildtype and mutant viruses were injected intradermally into the shaved backs of three rabbits. By using the same rabbits simultaneously for both wild-type and mutant viruses, we avoided differences due to animal variation. The sizes of the lesions were measured throughout the course of infection and the results obtained with 106 pfu of virus are presented in Fig.  3 . For the first few days, the lesions formed by wild-type and mutant viruses were similar, suggesting little or no difference in the innate abilities of these viruses to replicate in rabbit skin. From day 5 on, however, lesions of the mutant virus were smaller in size when compared to those produced by the parental virus. Similar results were also obtained with the other dilutions of virus (data not shown). Analysis of sera from two of the infected rabbits indicated that antibody capable of mediating complement-enhanced neutralization in vitro was detectable at day 6 and increased significantly thereafter (data not shown). These results suggested that VCP plays a significant role in evading the host immune response.
VCP Inhibits Antibody-Dependent, Complement-Enhanced Neutralization by a C4-Independent Pathway of Complement Activation. Based on previous studies (19) , we anticipated that the complement-enhanced neutralization of vaccinia virus was mediated by the classical pathway of complement activation. To test this, we used serum from normal and C4-deficient guinea pigs as complement sources. Unexpectedly, both sources of complement enhanced virus neutralization in an antibody-dependent fashion (Fig. 4) . Moreover, this enhancement was prevented by medium from wild-type but not from uninfected or mutant virus-infected cells (Fig.  4) . These results, which were obtained with commercial C4-deficient guinea pig serum, were replicated by using well characterized serum from a colony of guinea pigs with a total genetic deficiency of C4 (20) maintained at the National Institutes of Health (a gift of M. M. Frank). To ensure that the 1:100 dilution of heat-inactivated polyclonal antiserum was not providing a minute amount of C4, the immunoglobulin G fraction was purified and used as the antibody source with similar results (data not shown).
To assess the role of the alternative pathway in complement-enhanced neutralization of vaccinia virus, we used standard or factor B-depleted human serum as the complement source. As shown in Fig. 5 , the undepleted complement source had some neutralization activity alone but activity was from Mock, Mutant, or WT-infected cells as described in Fig. 2 . Antiserum was at a final dilution of 1:100. Normal guinea pig (C-gp) or C4-deficient guinea pig (C4D-gp) complement sources were either absent (0) or at the final dilution indicated below the graph. The data for C-gp and C4D-gp represent the mean (+SD) of six and five experiments, respectively. In each individual experiment, the data were standardized to the titers of the virus without antibody or complement.
greatly enhanced in the presence of antibody. The antibodydependent activity was largely abrogated by medium from wild-type vaccinia virus-infected cells when a 1:20 dilution of complement was used and was partially abrogated when the 1:10 dilution of complement was used. As expected, medium from uninfected cells or from cells infected with the mutant virus had little effect. The factor B-depleted human serum, however, had little or no ability to neutralize vaccinia virus itself or to enhance neutralization in the presence of antibody (Fig. 5) . The complement-enhancing activity of the factor B-depleted human serum was restored by addition of physiological amounts of factor B (Fig. 5) , indicating a role for alternative pathway components in this system.
Effect of VCP on Virus Pathogenicity in C4-Deficient Guinea
Pigs. The availability of C4-deficient guinea pigs (20) allowed us to investigate the role of VCP in animals with a genetic lesion resulting in the absence of the classical complement pathway. Ten-fold dilutions of wild-type or mutant (vSIGK3) virus were injected intradermally and the progression of skin lesion sizes was measured. As observed with rabbits, the lesions formed by mutant virus on the backs of the C4-deficient guinea pigs were smaller than those formed by the parental virus (Fig. 6) . Similar results were obtained when normal 2/NCR strain guinea pigs were studied under the same conditions (data not shown). 
DISCUSSION
The purpose of the present study was to evaluate the possibility that VCP has a role in regulating the host immune response to vaccinia virus. The data reported indicate that VCP can prevent antibody-dependent enhanced neutralization of vaccinia virus mediated by complement derived from rabbits, guinea pigs, or humans. Unexpectedly, enhanced neutralization of vaccinia virus did not require the C4 component of the classical pathway of complement activation. Thus, antibody-dependent, complement-enhanced neutralization was achieved with C4-deficient guinea pig serum, which has no classical pathway complement activity (20) , but was not achieved with factor B-depleted human serum, which is defective in the alternative pathway of complement activation. In the latter case, neutralization-enhancing ability was restored by addition of purified factor B. This indicates that components of the alternative pathway of complement activation play an important role in our assay system. Further studies are needed to resolve differences between our results and those of Leddy et al. (19) , who reported that the classical pathway of complement activation makes a major contribution to enhanced neutralization of vaccinia virus. The poxviruses, of which vaccinia is the prototype, are arguably the most complex of all animal viruses, with 100 or more polypeptides in the infectious particle (21) . It is possible that our (25, 26) .
Most significant was our finding that deletion of the gene encoding VCP results in measurable attenuation of virus pathogenicity in rabbits. Initially, the lesions caused by intradermal inoculation of wild-type and mutant viruses appeared similar, but after day 5 the latter diminished in size. This timing correlated with the detection of antibody capable of supporting complement-enhanced virus neutralization in vitro. Attenuation of the mutant virus was also demonstrated with C4-deficient guinea pigs, consistent with in vitro data regarding the ability of VCP to regulate a C4-independent pathway of complement activation. These results support the thesis that vaccinia virus has acquired the ability to regulate the complement cascade for the purpose of evading the host immune response.
